A Phase 2 interventional study of SHR-1210 in Hepatocellular Carcinoma Non-Resectable, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing camrelizumab in Carcinoma, Hepatocellular — 19 open to participants now, 24 under way, 8 of them phase 3. camrelizumab · Carcinoma, Hepatocellular.
Among the 44 studies testing camrelizumab in Carcinoma, Hepatocellular, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 24 in phase 2, and was the 2nd registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →19 of the 44 studies testing camrelizumab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Guohui Xu · Sites in China
Ages 18–80
Sun Yat-sen University · Sites in China
Ages 18–75
Wen Tianfu · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 33 · Phase 3 9
First in 2016; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 51 across the 44 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 44 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd.: 5 open now, 7 under way, 4 of them phase 3. Of 5 finished, 3 (60%) have results posted.
Among the 13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by enrollment, is the only one that started in 2016, is one of 4 in phase 2, and was the 2nd registered.
Jiangsu HengRui Medicine Co., Ltd.’s Carcinoma, Hepatocellular studies by the year they started, since 2014.
5 of the studies testing camrelizumab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05062837Phase 3Guangxi Medical UniversityHepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | 2026-12-30 |
| NCT05738616Phase 3Wen TianfuLenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) | 2027-05-01 |
| NCT07618546Henan Cancer HospitalA Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors | 2027-03-31 |
| NCT06360042Peking University Cancer Hospital & InstituteAnti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | 2027-03-31 |
| NCT07100392Fudan UniversityTauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 44 studies testing camrelizumab in Carcinoma, Hepatocellular, from their registry updates:
Among Jiangsu HengRui Medicine Co., Ltd.’s 13 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
This a randomized controlled Phase 2/3 study to evaluate the efficacy and safety of SHR-1210 in subjects with advanced HCC who failed or intolerable to prior systemic treatment. The primary study hypothesis is that SHR-1210 treatment improves Objective Response Rate and Overall Survival when compare with SOC.
In June 2017, this study was revised to expand the Phase 2 part to enroll more subjects and remove the Phase 3 part under the same protocol. A Phase 3 study will be initiated separately.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
Biological: SHR-1210
Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks
Biological: SHR-1210
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Objective Response Rate
Tumour responses were evaluated by the independent review committee (IRC) according to RECIST 1.1.The primary endpoints were the proportion of patients with a IRC-assessed objective response (defined as the percentage of patients whose best overall response was confirmed complete or partial response).
Time frame: approximate 3 years
6-month Overall Survival Rate
6-month overall survival rate (defined as cumulative overall survival rate from the date of the first dose to 6 months)
Time frame: from the date of the first dose to 6 months
Duration of Response
time from first response to progression or death base on the IRC assessment
Time frame: approximate 3 years
Adverse Events
Number of Subjects with one or more adverse events as assessed by CTCAE 4.03
Time frame: approximate 3 years
Overall Survival
Time from first dose to death from any cause
Time frame: approximate 3 years
| Milestone | SHR-1210 Q2W | SHR-1210 Q3W |
|---|---|---|
| Started | 111 | 109 |
| Treated | 109 | 108 |
| Completed | 72 | 81 |
| Not completed | 39 | 28 |
Tumour responses were evaluated by the independent review committee (IRC) according to RECIST 1.1.The primary endpoints were the proportion of patients with a IRC-assessed objective response (defined as the percentage of patients whose best overall response was confirmed complete or partial response).
| percentage of participants | SHR-1210 Q2W | SHR-1210 Q3W |
|---|---|---|
| Objective Response Rate | 11.9 (6.5 to 19.5) | 16.7 (10.2 to 25.1) |
6-month overall survival rate (defined as cumulative overall survival rate from the date of the first dose to 6 months)
| percentage of participants | SHR-1210 Q2W | SHR-1210 Q3W |
|---|---|---|
| 6-month Overall Survival Rate | 75.9 (66.6 to 82.9) | 73.0 (63.6 to 80.4) |
time from first response to progression or death base on the IRC assessment
| months | SHR-1210 Q2W | SHR-1210 Q3W |
|---|---|---|
| Duration of Response | 30.4 (2.8 to NA) | 30.5 (5.4 to NA) |
Number of Subjects with one or more adverse events as assessed by CTCAE 4.03
| participants | SHR-1210 Q2W | SHR-1210 Q3W |
|---|---|---|
| Adverse Events | 109 | 108 |
Time from first dose to death from any cause
| months | SHR-1210 Q2W | SHR-1210 Q3W |
|---|---|---|
| Overall Survival | 14.3 (11.5 to 19.5) | 13.2 (9.4 to 16.3) |
Collected over approximate 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SHR-1210 Q2W | 27/109 (24.8%) | 50/109 (45.9%) | 108/109 (99.1%) |
| SHR-1210 Q3W | 29/108 (26.9%) | 46/108 (42.6%) | 107/108 (99.1%) |
| Event | SHR-1210 Q2W | SHR-1210 Q3W |
|---|---|---|
| Disease progressionGeneral disorders | 13/109 | 9/108 |
| Hepatic function abnormalHepatobiliary disorders | 2/109 | 6/108 |
| Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/109 | 4/108 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 2/109 | 4/108 |
| Hepatic failureHepatobiliary disorders | 4/109 | 3/108 |
| Multiple organ dysfunction syndromeGeneral disorders | 3/109 | 3/108 |
| Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/109 | 2/108 |
| Aspartate aminotransferase increasedInvestigations | 3/109 | 0/108 |
| DeathGeneral disorders | 0/109 | 2/108 |
| Intracranial tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/109 | 2/108 |
| Event | SHR-1210 Q2W | SHR-1210 Q3W |
|---|---|---|
| Haemangioma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 69/109 | 76/108 |
| Aspartate aminotransferase increasedInvestigations | 52/109 | 48/108 |
| Alanine aminotransferase increasedInvestigations | 47/109 | 46/108 |
| Blood bilirubin increasedInvestigations | 40/109 | 38/108 |
| Platelet count decreasedInvestigations | 35/109 | 39/108 |
| ProteinuriaRenal and urinary disorders | 36/109 | 29/108 |
| White blood cell count decreasedInvestigations | 24/109 | 31/108 |
| AnaemiaBlood and lymphatic system disorders | 27/109 | 28/108 |
| Gamma-glutamyltransferase increasedInvestigations | 17/109 | 28/108 |
| Weight increasedInvestigations | 27/109 | 21/108 |
| Age, Continuous(years) | SHR-1210 Q2W | SHR-1210 Q3W | Total |
|---|---|---|---|
| Median | 48.0 (25 to 80) | 49.5 (23 to 76) | 49.0 (23 to 80) |
| Sex: Female, Male(Participants) | SHR-1210 Q2W | SHR-1210 Q3W | Total |
|---|---|---|---|
| Female | 11 | 10 | 21 |
| Male | 98 | 98 | 196 |
| Race and Ethnicity Not Collected(Participants) | SHR-1210 Q2W | SHR-1210 Q3W | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | SHR-1210 Q2W | SHR-1210 Q3W | Total |
|---|---|---|---|
| China | 109 | 108 | 217 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Mar 2020, 39 months.
Results were first posted in Mar 2024, 4 years after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 39 months is close to that.
Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Camrelizumab
Jiangsu HengRui Medicine Co., Ltd. →